| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 3,042 | 3,812 | 3,410 | 3,137 | 3,312 | 3,581 | 3,699 | 3,717 | 3,510 | 3,584 | 4,102 | 3,887 | 3,536 | 4,016 | 4,081 | 3,985 | 4,366 | 3,973 | 4,365 | 4,307 | 4,395 | 4,342 | 5,026 | 5,241 | 4,645 | 5,536 | 5,547 | 5,534 | 5,288 | 5,421 | 5,882 | 5,845 | 5,801 | 6,406 | 6,766 | 6,690 | 6,332 | 6,785 | 7,152 | 7,183 |
| Expenses | 2,585 | 2,784 | 2,669 | 2,688 | 3,138 | 3,039 | 3,070 | 2,970 | 3,076 | 2,879 | 3,278 | 3,095 | 3,219 | 3,213 | 3,310 | 3,300 | 3,443 | 3,084 | 3,486 | 3,613 | 3,743 | 3,297 | 3,862 | 3,938 | 3,810 | 4,283 | 4,294 | 4,248 | 4,568 | 4,232 | 4,526 | 4,403 | 4,748 | 4,835 | 4,944 | 5,051 | 4,847 | 4,978 | 5,165 | 5,084 |
| EBITDA | 457 | 1,028 | 741 | 450 | 174 | 543 | 629 | 748 | 434 | 705 | 824 | 792 | 317 | 803 | 771 | 685 | 923 | 889 | 879 | 694 | 652 | 1,045 | 1,164 | 1,303 | 835 | 1,253 | 1,253 | 1,286 | 720 | 1,190 | 1,356 | 1,442 | 1,053 | 1,571 | 1,821 | 1,639 | 1,484 | 1,807 | 1,986 | 2,099 |
| Operating Profit % | 13 % | 26 % | 21 % | 12 % | 4 % | 15 % | 16 % | 17 % | 12 % | 16 % | 18 % | 19 % | 8 % | 16 % | 16 % | 16 % | 19 % | 21 % | 18 % | 15 % | 13 % | 23 % | 22 % | 24 % | 17 % | 22 % | 22 % | 22 % | 13 % | 20 % | 21 % | 23 % | 16 % | 23 % | 25 % | 22 % | 20 % | 25 % | 26 % | 27 % |
| Depreciation | 136 | 149 | 158 | 177 | 270 | 204 | 229 | 258 | 632 | 213 | 302 | 522 | 285 | 241 | 282 | 293 | 510 | 268 | 283 | 278 | 346 | 269 | 265 | 248 | 285 | 261 | 253 | 248 | 290 | 254 | 299 | 272 | 346 | 239 | 290 | 233 | 288 | 247 | 272 | 280 |
| Interest | 43 | 64 | 64 | 31 | 48 | 32 | 35 | 59 | 33 | 28 | 42 | 9 | 35 | 35 | 44 | 44 | 45 | 52 | 46 | 46 | 53 | 46 | 39 | 48 | 28 | 30 | 38 | 21 | 18 | 18 | 26 | 32 | 34 | 16 | 26 | 30 | 18 | 18 | 15 | 15 |
| Profit Before Tax | 390 | 892 | 595 | 322 | -82 | 401 | 444 | 514 | -137 | 557 | 574 | 340 | 199 | 620 | 509 | 449 | 501 | 663 | 681 | 506 | 328 | 799 | 926 | 1,022 | 544 | 996 | 996 | 1,054 | 448 | 975 | 1,100 | 1,218 | 745 | 1,375 | 1,594 | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 |
| Tax | 106 | 242 | 43 | 54 | 5 | 57 | 74 | 129 | -74 | 132 | 139 | -63 | 46 | 175 | 142 | 127 | 144 | 216 | 207 | 167 | 89 | 233 | 266 | 270 | 132 | 286 | 287 | 297 | 77 | 268 | 303 | 410 | 224 | 377 | 439 | 405 | 327 | 436 | 484 | 342 |
| Net Profit | 284 | 650 | 552 | 269 | -87 | 344 | 370 | 385 | -63 | 425 | 435 | 404 | 153 | 446 | 367 | 322 | 358 | 447 | 475 | 339 | 239 | 566 | 659 | 752 | 412 | 710 | 709 | 757 | 371 | 706 | 797 | 808 | 522 | 998 | 1,155 | 1,068 | 932 | 1,176 | 1,305 | 1,575 |
| EPS in ₹ | 3.24 | 8.09 | 6.76 | 3.24 | -1.16 | 4.22 | 4.41 | 4.66 | -0.77 | 5.08 | 5.25 | 4.98 | 2.22 | 5.60 | 4.68 | 4.12 | 4.56 | 5.93 | 5.85 | 4.35 | 3.05 | 7.17 | 8.25 | 9.28 | 5.13 | 8.86 | 8.82 | 9.03 | 4.49 | 8.51 | 9.78 | 9.92 | 6.51 | 12.34 | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 |
Cipla
1,463.05
+47.45
(3.35%)
Market Cap
1,18,158.10 Cr
EPS
51.05
PE Ratio
22.92
Dividend Yield
0.92 %
Industry
Healthcare52 Week High
1,702.05
52 Week Low
1,317.25
PB Ratio
4.03
Debt to Equity
0.03
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from32 analysts
Company News
View All News
Cipla Receives FDA Approval for Paclitaxel Injectable Suspension1 day ago
Cipla has obtained final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). This approval allows Cipla to manufacture and market this generic version of the cancer treatment in the United States.
Cipla Schedules Board Meeting for Q4 Results4 days ago
Cipla Limited has announced that its Board of Directors will meet on May 13 to consider and approve the financial results for the fourth quarter and the fiscal year ended March 31, 2023.
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,687.55 | #1 4,04,899.77 | 33.61 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 47.60 | |
5,589.30 | 1,48,378.35 | 69.15 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 47.92 | |
1,463.05 | #3 1,18,158.10 | #4 22.92 | #4 26,520.70 | #4 14.17 | #3 4,155 | #2 47.38 | 50.89 | |
3,129.00 | 1,05,899.58 | 56.83 | 10,785.70 | 11.59 | 1,656 | 13.54 | 45.29 | |
2,350.50 | 96,976.58 | 46.77 | 10,615.60 | 19.57 | 1,942 | -16.38 | 48.68 | |
1,109.50 | 92,582.82 | #1 17.01 | 28,905.40 | 12.36 | 5,578 | 1.69 | 40.66 | |
1,969.25 | 89,904.33 | 30.58 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 46.62 | |
868.85 | 87,426.64 | 18.74 | 19,831.50 | 13.82 | 3,831 | 29.92 | 44.56 | |
29,641.10 | 62,985.27 | 46.40 | 6,097.20 | 10.80 | 1,201 | 16.01 | 48.36 | |
1,082.45 | 62,868.87 | 17.41 | 29,559.20 | 17.55 | 3,169 | -10.04 | 41.61 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
14.17 %
Net Income Growth
46.55 %
Cash Flow Change
27.68 %
ROE
29.60 %
ROCE
23.78 %
EBITDA Margin (Avg.)
12.03 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 15,718 | 21,128 | 21,037 | 22,861 | 23,963 | 23,663 | 25,152 | 27,101 | 29,463 | 32,718 |
| Fixed Assets | 6,830 | 9,369 | 9,492 | 9,950 | 9,608 | 9,683 | 9,516 | 9,683 | 9,161 | 9,607 |
| Current Assets | 7,591 | 8,841 | 8,736 | 10,814 | 12,427 | 11,706 | 13,210 | 14,711 | 16,805 | 19,392 |
| Capital Work in Progress | 581 | 2,061 | 1,683 | 981 | 676 | 825 | 969 | 766 | 1,093 | 1,153 |
| Investments | 390 | 758 | 973 | 1,259 | 2,554 | 1,471 | 2,710 | 2,551 | 3,662 | 5,449 |
| Other Assets | 7,917 | 8,940 | 8,889 | 10,670 | 11,125 | 11,684 | 11,957 | 14,101 | 15,547 | 16,509 |
| Total Liabilities | 15,718 | 21,128 | 21,037 | 22,861 | 23,963 | 23,663 | 25,152 | 27,101 | 29,463 | 32,718 |
| Current Liabilities | 3,881 | 7,776 | 3,374 | 3,832 | 3,772 | 4,393 | 4,591 | 4,913 | 5,110 | 5,246 |
| Non Current Liabilities | 854 | 1,486 | 4,682 | 4,447 | 4,848 | 3,212 | 1,975 | 1,071 | 640 | 670 |
| Total Equity | 10,982 | 11,866 | 12,982 | 14,582 | 15,344 | 16,057 | 18,586 | 21,117 | 23,714 | 26,802 |
| Reserve & Surplus | 10,629 | 11,356 | 12,383 | 14,068 | 14,851 | 15,602 | 18,165 | 20,680 | 23,246 | 26,545 |
| Share Capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 389 | 312 | -248 | 243 | -345 | 234 | 141 | -132 | -97 | -49 |
| Investing Activities | -950 | -4,533 | -1,304 | -834 | -1,688 | 114 | -2,374 | -1,858 | -2,376 | -2,983 |
| Operating Activities | 1,173 | 1,741 | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | 3,238 | 4,134 |
| Financing Activities | 165 | 3,104 | -1,326 | -386 | -349 | -2,949 | -1,240 | -1,600 | -958 | -1,200 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 36.73 % | 36.72 % | 36.12 % | 36.11 % | 33.63 % | 33.61 % | 33.61 % | 33.61 % | 33.55 % | 33.47 % | 33.47 % | 33.47 % | 33.47 % | 30.91 % | 30.92 % | 29.19 % |
| FIIs | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 25.74 % | 25.73 % | 25.83 % | 27.81 % | 28.80 % | 26.65 % |
| DIIs | 16.79 % | 15.91 % | 17.41 % | 17.61 % | 17.72 % | 17.12 % | 19.71 % | 21.13 % | 22.10 % | 24.34 % | 24.18 % | 24.33 % | 24.42 % | 24.95 % | 24.16 % | 27.71 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 16.14 % | 16.01 % | 15.97 % | 15.55 % | 15.41 % | 14.83 % | 14.72 % | 14.85 % | 14.66 % | 14.45 % | 14.34 % | 14.20 % | 14.24 % | 14.16 % | 14.29 % |
| Others | 30.23 % | 31.22 % | 30.47 % | 30.30 % | 33.10 % | 33.86 % | 31.84 % | 30.53 % | 29.50 % | 27.53 % | 2.16 % | 2.12 % | 2.08 % | 2.09 % | 1.95 % | 2.15 % |
| No of Share Holders | 3,64,796 | 4,08,401 | 4,10,831 | 4,51,365 | 4,18,584 | 4,18,910 | 3,88,864 | 4,04,182 | 4,75,293 | 4,66,513 | 4,26,861 | 4,25,731 | 4,36,154 | 4,63,569 | 4,70,234 | 5,25,114 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2 | 3 | 3 | 4 | 5 | 5 | 8.5 | 13 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.37 | 0.57 | 0.71 | 0.49 | 0.49 | 0.56 | 0.57 | 0.9 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
1 day ago
1 day agoBoard Meeting Intimation for Quarter And Year Ended 31St March 2025 Under SEBI Listing Regulations4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 19, 2025
Mar 19, 2025USFDA Inspection At Analytical Testing Facility Of Sitec In Mahape Navi Mumbai IndiaFeb 20, 2025
Feb 20, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 20, 2025
Feb 20, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionFeb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Feb 10, 2025Update On USFDA Inspection At CompanyS Manufacturing Facility In Virgonagar Bengaluru IndiaFeb 08, 2025
Feb 08, 2025Announcement under Regulation 30 (LODR)-AcquisitionFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 28, 2025
Jan 28, 2025Integrated Filing (Financial)Jan 28, 2025
Jan 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 28, 2025
Jan 28, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated 28Th January 2025Jan 28, 2025
Jan 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 28, 2025
Jan 28, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 28, 2025
Jan 28, 2025Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended 31St December 2024.Jan 28, 2025
Jan 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 23, 2025
Jan 23, 2025USFDA Inspection At Manufacturing Facility Of Medispray In Kundaim Goa IndiaJan 20, 2025
Jan 20, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 17, 2025
Jan 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 15, 2025
Jan 15, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 14, 2025
Jan 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 08, 2025
Jan 08, 2025Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Tuesday 28Th January 2025Jan 06, 2025
Jan 06, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 05, 2024
Dec 05, 2024Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Dec 02, 2024
Dec 02, 2024Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Dec 02, 2024
Dec 02, 2024Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Nov 30, 2024
Nov 30, 2024Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Nov 28, 2024
Nov 28, 2024Disclosure Under Regulation 30(5) Of The SEBI (LODR) Regulations, 2015Nov 18, 2024
Nov 18, 2024Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSNov 15, 2024
Nov 15, 2024USFDA Inspection At Company''s Manufacturing Facility In Virgonagar, Bengaluru, IndiaNov 13, 2024
Nov 13, 2024Announcement under Regulation 30 (LODR)-Change in DirectorateNov 12, 2024
Nov 12, 2024Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 02, 2024
Nov 02, 2024Update On USFDA Inspection At Company''s Manufacturing Facility In Goa, IndiaOct 30, 2024
Oct 30, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 29, 2024
Oct 29, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 29, 2024
Oct 29, 2024Board Meeting Outcome for Outcome Of Board Meeting Dated 29Th October 2024Oct 29, 2024
Oct 29, 2024Announcement under Regulation 30 (LODR)-Investor PresentationOct 29, 2024
Oct 29, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 29, 2024
Oct 29, 2024Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30Th September 2024Oct 29, 2024
Oct 29, 2024Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 25, 2024
Oct 25, 2024Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations, 2015')Oct 17, 2024
Oct 17, 2024Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotOct 14, 2024
Oct 14, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 11, 2024
Oct 11, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 09, 2024
Oct 09, 2024Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 05, 2024
Oct 05, 2024Technical Indicators
RSI(14)
Neutral 50.89
ATR(14)
Less Volatile 44.41
STOCH(9,6)
Neutral 44.68
STOCH RSI(14)
Neutral 35.75
MACD(12,26)
Bearish -5.52
ADX(14)
Weak Trend 15.92
UO(9)
Bearish 54.14
ROC(12)
Downtrend And Accelerating -4.00
WillR(14)
Neutral -35.98
About Cipla
Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS therapeutic areas. Cipla has a global presence with manufacturing facilities and operations in India and international markets, including the United States, South Africa, and other countries. The company focuses on developing and producing generic and branded generic medicines, as well as expanding into consumer healthcare, biosimilars, and specialty business through its New ventures segment.
Website
Chairperson NameY K Hamied
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
